Products
EXJADE cpr disp 500 mg 84 pce

EXJADE cpr disp 500 mg 84 pce

7680574660119 CH-57466 V03AC03 06.99.0.

Active substances:

Deferasiroxum

No images available

Details

Product number: 5746603
CPT: -
Packaging group: 84
Unit: Tablette(n)
Composition: deferasiroxum 500 mg, crospovidonum, lactosum monohydricum 543.6 mg, cellulosum microcristallinum, povidonum K 30, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.680 mg.

Articles (1)

Exjade 500 mg, dispergierbare Tabletten

Tabletten

View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC

Allemand

06/04/2022

Professional SmPC

Français

06/04/2022

Professional SmPC

Italien

06/04/2022

Patient information leaflet

Allemand

25/08/2020

Patient information leaflet

Français

25/08/2020

Patient information leaflet

Italien

25/08/2020

Detailed composition

Substance	Quantity	Type	Category
deferasiroxum	500.0 MG	Substance	Wirkstoff (Principe actif)
crospovidonum	-	Substance	HNIDK
lactosum monohydricum	543.6 MG	Substance	HBESI
cellulosum microcristallinum	-	Substance	HNIDK
povidonum K 30	-	Substance	HNIDK
natrii laurilsulfas	-	Substance	Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
silica colloidalis anhydrica	-	Substance	HNIDK
magnesii stearas	-	Substance	HNIDK
natrium	0.68 MG	Substance	HBESI

Authorization holder

Novartis Pharma Schweiz AG

6343 Risch

Authorization information

Swissmedic authorization number: 57466
Drug name: Exjade, dispergierbare Tabletten
Galenic form: TABSU
ATC Code: V03AC03
Authorization status: Z
Dispensation category: B
First authorization: 03/11/2005
Authorization expiration date: 31/12/9999
IT number: 06.99.0.
Domain: Human medicine

Field of application

Behandlung der transfusionsbedingten Hämosiderose. Behandlung von chronischer Eisenüberladung, die eine Chelattherapie erfordert, bei Patienten mit nicht-transfusionsabhängiger Thalassämie ab 10 Jahren.